

Amendment to CEO Conditions of Employment

BRISBANE & MELBOURNE, 4th March 2019: Anatara Lifesciences (ASX:ANR) is pleased to advise that the Board of Directors have shortened and concluded the probationary period for Mr Steven Lydeamore, Chief Executive Officer (CEO), as was outlined in the key terms and conditions of employment announced to the market on 14th November 2018.

Commenting on the amendment, Anatara's Chair, Sue MacLeman said, "From the outset, the Anatara Board of Directors have been impressed with Steve's dedication to his role; having contributed to the inaugural Product Development Advisory Board and embarked on an investor roadshow during his first week in the role last December. Steve continues to demonstrate eagerness to propel Anatara towards partnering our first human product candidate, the Gastrointestinal ReProgramming (GaRP) dietary supplement, aimed at restoring and maintaining a healthy gut."

With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders. Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) are two such conditions identified by Anatara with a strong market opportunity and unmet need.

Looking ahead, Anatara remains focused on its new business strategy in human health, shifting focus towards building a pipeline of gastrointestinal health products. Through a targeted development program, the Company is committed to delivering positive outcomes for patients and driving value for shareholders, by developing scientifically innovative and commercially attractive products for gut health in areas needing improved or new therapeutic options.

For more information please contact:

Investor inquiries	Media inquiries
Sue MacLeman Chair Anatara Lifesciences +61 (0) 437 211 200 smacleman@anatara.com	Jane Lowe Managing Director IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au

About Anatara Lifesciences

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.